The terms, per the grant. On April 30, 2024, Translate Bio was issued US11969480B2, covering processes of preparing mRNA-loaded lipid nanoparticles. The CPC tags — A61K 48/0091 (gene-therapy preparation), A61K 9/5123 (lipid particles), plus the B01F mixing-apparatus series — describe the manufacturing operations that load mRNA into the delivery particle.

What the claims actually fence off is narrower and more specific than the title suggests, and the specificity is the point for a deals desk. Independent claim 1 covers a process of encapsulating mRNA in preformed empty lipid nanoparticles — particles whose lipid component is a cationic lipid, a non-cationic lipid, a PEG-modified lipid and optionally cholesterol — by adding a first volume of mRNA solution to the LNP suspension, then adding further volumes until a target molar ratio of cationic lipid to mRNA is reached, "without intervening periods of heating or mixing." Independent claim 3 mirrors that sequence in the opposite order: adding the LNP suspension into the mRNA solution. A third independent claim, claim 8, reaches a manufacturing method that mixes one set of empty LNPs with mRNA and then combines the result with a second set of empty LNPs, so that two lipid formulations can be blended in a single composition.

Why process IP anchors supply deals: the bottleneck in scaling mRNA medicine is reproducible, high-quality manufacturing. IP covering the mixing and loading processes is exactly what a manufacturing or supply collaboration is written around, because it determines yield, consistency, and cost-of-goods.

“The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation.”— U.S. Patent No. 11,969,480 source

Read the dependent claims and the manufacturing detail becomes more concrete still — and detail is what a process license can be priced against. The grant specifies continuous addition "at a constant flow rate" (claim 10) or at "a flow rate that increases or decreases over time" (claim 11); it specifies forming the empty LNPs by mixing a lipid solution in ethanol with an aqueous solution (claim 6), running that aqueous solution with citrate (claim 16), and removing ethanol "by tangential flow filtration" (claim 17). It claims a process window in which the empty-LNP suspension sits at "about 60° C. to about 70° C." while the mRNA solution is held at ambient temperature (claim 5), and a particle-size target in which "greater than about 90% of the preformed empty LNPs have a size ranging from 75–150 nm" (claim 7). Each of those is a named unit operation a contract manufacturer would have to either practice or design around.

The structure point: a process-IP deal supports supply agreements, contract-manufacturing arrangements, and process licenses rather than drug royalties. The value scales with manufacturing volume across partners and is partly insulated from any single product's clinical fate. For a model, that is an infrastructure-grade royalty stream — the kind of asset whose revenue tracks doses produced rather than a single program's read-out. A grant that fixes flow rate, temperature, particle size and the ethanol-removal step gives the licensor concrete inspection points, and gives the licensee a defined freedom-to-operate envelope, which is the part of a manufacturing deal that lawyers actually negotiate.

The two-population claim (claims 8, 18 and 19, the last two allowing the first and second LNP sets to share "the same lipid formulation" or carry "different lipid formulations") is worth flagging on its own. A process that lets a manufacturer blend two separately encapsulated lipid populations into one composition is a flexibility feature — it widens the set of products a single licensed line can make, which is the sort of thing that widens the addressable footprint of a supply deal.

What the grant does not promise: a clinical result or an approval — it is a manufacturing method. It is an exclusivity claim on a way of making the product, valuable to the extent partners need that process, and constrained to the specific encapsulation sequences, ratios and unit operations the claims recite.

It helps to read the grant against the way mRNA-LNP manufacturing is actually staged, because that is where a process claim either bites or does not. A conventional encapsulation can form the particle and load the nucleic acid in a single step; this grant claims the alternative in which empty particles are made first and the mRNA is introduced afterward, volume by volume, into preformed carriers. The dependent claims that govern that introduction are the commercially sensitive ones. Claim 2 ties the first addition to "an at least 10-fold molar excess of cationic lipid to mRNA," while claim 4 fixes "an approximately equimolar ratio." Those are not incidental details; they are the kind of process set-points that determine encapsulation efficiency, and a manufacturer running a licensed line would be operating inside or outside them. A counterparty evaluating a process license reads exactly these numbers to judge how much of its own intended operation falls within the claimed envelope.

The order-of-addition pair, claims 1 and 3, also matters for how a license is drafted. Because the grant separately claims adding mRNA into the LNP suspension and adding the LNP suspension into the mRNA, a manufacturer cannot escape the estate simply by reversing the direction of the two streams. For a deals desk modeling freedom-to-operate, that symmetry is what gives the grant its practical weight: it closes the obvious work-around, which raises the likelihood that a partner needs a license rather than a redesign. Claim 12 and claim 15 each add that the continuous addition "is followed by a period of mixing," capturing the finishing step that drives uniformity, while claims 13 and 14 mirror the flow-rate options for the reversed-order process. The effect is a claim set that brackets the realistic ways of running the operation, which is precisely what makes process IP a durable royalty foundation rather than a narrow, easily-circumvented method.

The takeaway: when an mRNA supply or manufacturing deal crosses the desk, the process grants are the load-bearing assets. Translate Bio's April 2024 LNP-process grant is a dated example of the manufacturing IP behind that deal layer — with claim language specific enough that a counterparty can read exactly which encapsulation steps a license would and would not cover.